Company intelligence / Profile preview

Grupo GENOM

São Paulo, São Paulo, Brazil

Ownership: Private
Development stage: Other

Overview

Genom is a Brazilian pharmaceutical company and a specialized business unit of Eurofarma Laboratórios. The company focuses on high-complexity therapeutic areas, primarily the Central Nervous System (CNS) and Ophthalmology, providing a wide range of branded generic medications. Genom's portfolio includes treatments for depression, anxiety, schizophrenia, and various ocular conditions such as glaucoma. By operating under the Eurofarma umbrella, Genom benefits from robust research, development, and manufacturing capabilities in Latin America. The company is a significant player in the Brazilian healthcare market, catering to specialized medical professionals and their patients.

Therapeutic areas: OphthalmologyPsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Grupo GENOM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grupo GENOM.

Explore the full profile